Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (56)	12/28/1999 9:05:00 AM
From: biowa	Respond to of 363

Walter, Thanks. Did he include a bubbly market in his price target? <g> ALX1-11 (Osteoporosis)...Results were presented in December of 1998 and P3 trials will start soon. (...do you know why P3 was not started any sooner???) I suspect dollars. As you observe, osteoporosis trials are long, no point in starting them if you're going to run out of money before they're done. Geller believes NPSP will probably partner ALX-0600. I wonder how having the Canadian government as a partner complicates/changes that... NPS-1776 As I said before, NPS has said (pre-merger) "one or more" outlicenses. IMO the prime candidates are 1506 and 1776. Glycine Re-uptake Inhibitors...The second, with Janssen, is in development for schizophrenia and dementia. Not much more was said about these...must be early, secret, or maybe Geller was running out of steam... NPS has published that they expect Janssen to select a candidate in this program in 2000. Clinical candidate? Pre-clinical lead? Once again, thanks Walter. Let's light this candle... biowa